Lymphocyte antigen 96 (LY96) is implicated in
tumorigenesis by modulating host immunity. However, an integrated pan-
cancer analysis of LY96 in prognosis and
immunotherapy across human
cancers is still lacking. Therefore, we analyzed the LY96 expression and its prognostic role in
tumors by multiple databases. We also investigated the correlation between LY96 and copy number, DNA methylation, somatic mutation,
microsatellite instability (MSI),
tumor mutation burden (TMB), tumor microenvironment (TME), and immune cell infiltration across human
cancers. In addition, the biological processes related to LY96 across various
tumors and the correlation between LY96 and 50% inhibitive concentration (IC50) of various drugs were investigated. We found that LY96 was differently expressed between
tumor and normal tissues and was significantly upregulated in most types of
cancers. LY96 was gradually upregulated from stages I to IV in several
cancers. Moreover, we found LY96 may play a prognostic role in most
cancers, and patients with high or low LY96 expression often show different clinical outcomes. LY96 was also associated with copy number, DNA methylation, somatic mutation, MSI, TMB, TME characteristics, and immune cell infiltration in
cancers. LY96 may also regulate classic
tumor-associated pathways in several
cancers and is related to drug resistance. This article may help to elucidate the role of LY96 in
tumorigenesis, which may promote the development of
immunotherapy and targeted
therapy in
cancers.